BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
8.95
-0.09 (-1.00%)
At close: Aug 18, 2026, 4:00 PM EDT
8.74
-0.21 (-2.34%)
After-hours: Aug 18, 2026, 4:58 PM EDT
BridgeBio Oncology Therapeutics Employees
BridgeBio Oncology Therapeutics had 106 employees as of March 31, 2026. The number of employees increased by 14 or 15.22% since the number was last reported on December 31, 2025.
Employees
106
Change
14
Growth
15.22%
Revenue / Employee
n/a
Profits / Employee
-$1,718,057
Market Cap
717.56M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 106 | 14 | 15.22% |
| Dec 31, 2025 | 92 | 30 | 48.39% |
| Dec 31, 2024 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Phathom Pharmaceuticals | 371 |
| REGENXBIO | 371 |
| Allogene Therapeutics | 152 |
| Neurogene | 131 |
| Cybin | 100 |
| Crescent Biopharma | 69 |
| CytomX Therapeutics | 69 |
BBOT News
- 2 days ago - BridgeBio Oncology price target lowered to $25 from $27 at JPMorgan - TheFly
- 7 days ago - BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 7 days ago - BridgeBio Oncology Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - BridgeBio Oncology Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - BridgeBio Oncology initiated with an Overweight at JPMorgan - TheFly
- 2 months ago - BridgeBio Oncology assumed with an Outperform at Oppenheimer - TheFly
- 2 months ago - BridgeBio Oncology Therapeutics Transcript: AGM 2026 - Transcripts